

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

Brilliant Violet 421(TM) anti-human CD38

RRID:AB_10983072

Type: Antibody

Proper Citation

BioLegend Cat# 303526, RRID:AB_10983072

Antibody Information

URL: http://antibodyregistry.org/AB_10983072

Proper Citation: BioLegend Cat# 303526, RRID:AB_10983072

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human CD38

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: Clone HIT2

Antibody ID: AB_10983072

Vendor: BioLegend

Catalog Number: 303526

Alternative Catalog Numbers: 303525

Record Creation Time: 20250820T015625+0000

Record Last Update: 20250820T121554+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD38.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD38.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Melo Garcia L, et al. (2025) Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells. Cell reports, 44(1), 115122.

Jakobsen NA, et al. (2025) Protocol for high-quality RNA sequencing, cell surface protein analysis, and genotyping in single cells using TARGET-seq. STAR protocols, 6(2), 103832.

Jakobsen NA, et al. (2024) Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging. Cell stem cell, 31(8), 1127.

Turkalj S, et al. (2023) GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells. Cell stem cell, 30(5), 722.

Turkalj S, et al. (2023) A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells. STAR protocols, 4(4), 102641.

Burton AR, et al. (2022) The memory B cell response to influenza vaccination is impaired in older persons. Cell reports, 41(6), 111613.

Gbyli R, et al. (2022) In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia, 36(5), 1313.

Baskar R, et al. (2022) Integrating transcription-factor abundance with chromatin accessibility in human erythroid lineage commitment. Cell reports methods, 2(3).